Rare EGFR and KRAS mutations and tumor response to EGFR TKI.

<p>PR is partial response, PD is progressive disease, –  =  no EGFR TKI treatment; (E) = erlotinib, (G) = gefitinib, ND = Not described.</p

Patient and tumor characteristics from samples sent to central laboratory for mutation analysis.

<p>SCC is squamous cell lung carcinoma. NSCLC-NOS is non-small cell lung cancer – not otherwise specified.</p

Flow chart for biopsy specimens sent in and result of mutation analysis.

<p>* 2 KRAS mutations are outside of the hotspot, these are probably non functional.</p

A: Overall survival in patients with non-small cell lung cancer treated with EGFR-TKI in the first and second line with or without an EGFR mutation. The median overall survival for patients with EGFR mutations (n = 14) was not reached, in patients with EGFR/KRAS WT it was 9 months (95% CI., 0–28 months, n = 31). 2B: Overall survival in patients with non-small cell lung cancer treated with EGFR-TKI in the first and second line with or without KRAS mutation. The median overall survival for patients with KRAS mutations was 20 months (95% CI., 0–46, n = 14), in patients with EGFR/KRAS WT it was 9 months (95% CI., 0–28 months, n = 31).

<p>A: Overall survival in patients with non-small cell lung cancer treated with EGFR-TKI in the first and second line with or without an EGFR mutation. The median overall survival for patients with EGFR mutations (n = 14) was not reached, in patients with EGFR/KRAS WT it was 9 months (95% CI., 0–28 months, n = 31). 2B: Overall survival in patients with non-small cell lung cancer treated with EGFR-TKI in the first and second line with or without KRAS mutation. The median overall survival for patients with KRAS mutations was 20 months (95% CI., 0–46, n = 14), in patients with EGFR/KRAS WT it was 9 months (95% CI., 0–28 months, n = 31).</p

Univariate and multivariate hazards ratios for overall survival in 248 patients with metastatic non-small cell lung cancer.

<p>HR>1 means a shorter survival.</p>*<p>denotes presence of metastasis at specific site.</p